CUVRIOR Drug Patent Profile

When do Cuvrior patents expire, and when can generic versions of Cuvrior launch?

Cuvrior is a drug marketed by Orphalan and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has forty-four patent family members in twenty-seven countries.

The generic ingredient in CUVRIOR is trientine tetrahydrochloride. There are ten drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the trientine tetrahydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Cuvrior

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 28, 2029. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for CUVRIOR

International Patents:	44
US Patents:	4
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	57
Patent Applications:	73
Drug Prices:	Drug price information for CUVRIOR
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for CUVRIOR
What excipients (inactive ingredients) are in CUVRIOR?	CUVRIOR excipients list
DailyMed Link:	CUVRIOR at DailyMed

See drug prices for CUVRIOR

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for CUVRIOR

Constraining patent/regulatory exclusivity:

TREATMENT OF ADULT PATIENTS WITH STABLE WILSON’S DISEASE WHO ARE DE-COPPERED AND TOLERANT TO PENICILLAMINE

NDA:

215760

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for CUVRIOR

Drug Class	Copper Chelator
Mechanism of Action	Copper Chelating Activity Metal Chelating Activity

Paragraph IV (Patent) Challenges for CUVRIOR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
CUVRIOR	Tablets	trientine tetrahydrochloride	300 mg	215760	1	2023-06-21

US Patents and Regulatory Information for CUVRIOR

CUVRIOR is protected by four US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on TREATMENT OF ADULT PATIENTS WITH STABLE WILSON’S DISEASE WHO ARE DE-COPPERED AND TOLERANT TO PENICILLAMINE.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Orphalan	CUVRIOR	trientine tetrahydrochloride	TABLET;ORAL	215760-001	Apr 28, 2022		RX	Yes	Yes	12,358,862		Y	Y
Orphalan	CUVRIOR	trientine tetrahydrochloride	TABLET;ORAL	215760-001	Apr 28, 2022		RX	Yes	Yes	10,988,436			Y
Orphalan	CUVRIOR	trientine tetrahydrochloride	TABLET;ORAL	215760-001	Apr 28, 2022		RX	Yes	Yes	12,358,861		Y	Y
Orphalan	CUVRIOR	trientine tetrahydrochloride	TABLET;ORAL	215760-001	Apr 28, 2022		RX	Yes	Yes	11,072,577
Orphalan	CUVRIOR	trientine tetrahydrochloride	TABLET;ORAL	215760-001	Apr 28, 2022		RX	Yes	Yes

International Patents for CUVRIOR

When does loss-of-exclusivity occur for CUVRIOR?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

China

Colombia

Croatia

Denmark

Eurasian Patent Organization

European Patent Office

Finland

Germany

Japan

Lithuania

Morocco

New Zealand

Poland

Portugal

San Marino

Saudi Arabia

Serbia

Singapore

Slovenia

South Korea

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering CUVRIOR around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	115080
Australia	2019263969
Australia	2024227767
Brazil	112020018451
Canada	3096423
China	111479798
China	114394904

CUVRIOR (cuvrior) market dynamics and financial trajectory: pricing, volume, payer behavior, and exclusivity-driven risk

Last updated: June 16, 2026

CUVRIOR revenue trajectory depends on four forces: how quickly the product converts prescriptions after launch, the extent of payer restriction versus clinical comparators, the timing of patent/exclusivity barriers to generic or biosimilar competition, and how much the manufacturer’s net price is compressed by rebates and coverage limits. Without authoritative, drug-specific financial disclosures and FDA/regulatory inventory for CUVRIOR in the US and key EU/ROW markets, a precise revenue forecast and timeline cannot be produced.

What is CUVRIOR and how is it marketed commercially (brand, label, geography)?

Featured snippet answer: Market dynamics start with three basics that determine addressable demand: the labeled indication, the dosage form(s), and where the product is reimbursed and sold.

Commercial drivers to map for CUVRIOR

• Indication scope: broader label areas expand prescriber pool and can reduce payer pushback if guideline-concordant.
• Dose and administration: once-daily vs titration, monitoring burden, and switchability affect adherence and payer willingness.
• Coverage type: formulary placement (preferred, non-preferred, PA required) and whether it is subject to step therapy or quantity limits.

Key questions that control early sales ramp

• Does CUVRIOR compete against established therapeutics with entrenched formulary status, or against off-label standards?
• Is the product positioned as “first-line,” “add-on,” or “switch” therapy in typical treatment algorithms?
• Are payer policies aligned with clinical trial endpoints, or do they restrict based on prior therapy use?

How do payer policies shape CUVRIOR net price and channel mix?

Featured snippet answer: Net price is usually the binding constraint for brand revenue after launch, with payer restrictions determining rebate levels, patient share, and channel mix.

Payer behavior that typically hits branded revenue

• Rebate intensity: high rebates reduce realized revenue even if gross sales rise.
• Formulary tiering: moving from preferred to non-preferred tier can cut scripts even if clinical demand stays stable.
• Prior authorization (PA): increases administrative friction and shifts prescribing patterns toward sites with specialist support.
• Step therapy: forces trial of cheaper alternatives before coverage for CUVRIOR.
• 340B and specialty distribution dynamics: can affect channel timing and reported revenue recognition.

Competitive reimbursement dynamics to assess

• Whether CUVRIOR is priced as a premium versus a close therapeutic alternative.
• Whether payers demand outcomes data or restrict to subpopulations with specific clinical criteria.

CUVRIOR vs competitors: which drugs most affect demand and pricing power?

Featured snippet answer: Demand and pricing power depend on how CUVRIOR stacks against closest-line comparators and whether clinicians view switching as safe and practical.

Demand levers for competitor sets

• Clinical differentiation: safety profile, efficacy magnitude, convenience, and contraindication handling.
• Switch economics: whether patients can move from comparator drugs with minimal washout or monitoring burden.
• Formulary lock-in: incumbent deals and contracting can delay conversion even when clinical advantage exists.
• Tolerability and persistence: adherence and discontinuation rates influence refill-driven sales.

Market share math that drives trajectory

• Patient starts (new to therapy) vs patient switches.
• Persistence (duration on therapy) and dose intensity (adherence to prescribed regimen).
• Share of prescriptions by specialty (e.g., oncology, rheumatology, cardiology) and site-of-care patterns.

When does CUVRIOR face generic competition and how does exclusivity expiration affect revenue?

Featured snippet answer: Brand revenue typically accelerates erosion starting at the first market entry of authorized or unapproved competitors, with additional drops when exclusivity and key patents expire.

Exclusivity and patent-driven inflection points to model

• Regulatory exclusivity (new chemical entity, new clinical investigation, pediatric exclusivity) if applicable.
• Orange Book patent expiry for:
  • active ingredient composition of matter,
  • formulation patents (e.g., specific salts, crystalline forms, dosing regimens),
  • method-of-use patents.
• Paragraph IV incentives, if ANDA filings occur and trigger 180-day exclusivity for the first challenger.
• Settlement agreements (where they exist) that can delay or accelerate generic entry.

Financial impact pattern

• Peak revenue often occurs after uptake is established but before first approval-to-launch competitive erosion.
• Post-expiry declines often follow a step function: initial discounting and formulary changes, then sustained erosion after multiple entrants.

What patents protect CUVRIOR and how strong is the patent estate?

Featured snippet answer: Patent strength determines delay to generic entry and how much substitution is blocked by formulation or method-of-use coverage.

How to evaluate patent estate strength

• Count of Orange Book listed patents for each NDA/NMA and each claim category.
• Remaining life by patent family: earliest expiry date across composition, formulation, and method-of-use.
• Claim breadth: whether competitors can design around by changing salt form, polymorph, particle size, dosage regimen, or patient subgroup.
• Litigation posture: whether patents are being defended in court and whether injunction risk exists.
• Geographic coverage: US first, then EU validation and national phase status.

Revenue link

• Strong formulation and method-of-use patents can preserve differentiated contracting even when composition patents expire.

Has CUVRIOR faced Paragraph IV challenges or patent litigation that changed the launch calendar?

Featured snippet answer: A Paragraph IV challenge increases the probability of earlier generic entry and can cap brand sales through earlier-than-planned erosion.

Litigation signals that matter financially

• ANDA filing timing relative to the earliest possible expiry.
• Whether a court stays an approval due to injunction risk.
• Whether settlements are “no design-around” agreements or allow limited competition.

Trajectory effect

• The market typically reprices peak sales and lifetime value when:
  • first challengers are granted 180-day exclusivity,
  • courts rule against brand,
  • generic entry dates are moved forward by settlements.

What is the Orange Book status of CUVRIOR?

Featured snippet answer: Orange Book listings determine the precise patent expiration map used to model generic entry risk.

A complete, accurate Orange Book status requires the NDA/NMA and the listed patents. The present prompt does not provide those identifiers, and a precise, drug-specific status cannot be generated.

What is the FDA status of CUVRIOR and how does approval pathway influence uptake?

Featured snippet answer: Approval pathway (standard vs priority review; potential expedited programs) can correlate with launch timing, but uptake is driven more by payer coverage and prescriber adoption.

Regulatory dynamics that affect commercialization

• Label breadth at launch: drives prescriber willingness and payer scope.
• Post-marketing commitments: can delay adoption if additional data is needed for safety or efficacy.
• Safety signals: can create payer restrictions or prescribing limits.
• Manufacturing capacity: stock-outs can cap early revenue and impair momentum.

What generic entry risks exist for CUVRIOR formulations and dosing regimens?

Featured snippet answer: The highest risk is typically where competitors can use a design-around strategy that avoids formulation and method-of-use patents while still meeting FDA bioequivalence requirements.

Design-around vectors

• Salt form / crystalline form for solid oral products
• Particle size / polymorph / solid state
• Drug-device combination
• Dosage regimen (titration schedule, loading doses, maintenance intervals)
• Patient subgroup claims in method-of-use patents

Commercial consequences

• If design-arounds exist, multiple ANDAs can launch around the same time.
• If the product depends on a narrow formulation or regimen, generic adoption can lag even after composition expiry.

How do manufacturing and supply chain constraints affect CUVRIOR financial performance?

Featured snippet answer: Supply constraints can delay net sales recognition and worsen channel allocation dynamics, while stable manufacturing supports consistent script conversion and refill capture.

Supply-side factors

• Single-source vs multi-source API and intermediate production
• Sterility or process validation for non-oral products
• Scale-up timeline and yield variability
• Allocation rules during shortages and their effect on prescriber confidence

CUVRIOR revenue sensitivity: what levers most change the financial trajectory?

Featured snippet answer: For branded pharmaceuticals, realized revenue is most sensitive to net pricing and volume ramp speed, with exclusivity expiration acting as a hard floor under long-term value.

Primary sensitivity levers

• Net price erosion rate (rebates, discounts, contracting shifts)
• Volume trajectory (starts, switching share, persistence)
• Competitor entry timing driven by patent and regulatory calendars
• Geographic rollout (US vs EU vs other markets)
• Formulary stability (preferred vs non-preferred over time)

Secondary levers

• Specialty distribution and buy-and-bill economics (if applicable)
• Patient assistance programs (if applicable)
• Safety updates or new label restrictions

Key Takeaways

• CUVRIOR financial trajectory is primarily driven by payer coverage intensity, net price erosion, and the timing and durability of patent/exclusivity barriers that govern generic entry.
• Revenue typically ramps with prescription conversion and persistence, then erodes quickly once competition begins, especially if payers re-tier the drug.
• The decisive near-term variable is exclusivity and patent expiry timing, including whether challengers file Paragraph IV and whether settlements accelerate or delay entry.
• A precise Orange Book status, litigation timeline, and quantified revenue forecast cannot be produced from the information provided.

FAQs

1. How do rebates and formulary tiering typically affect net sales for new branded drugs like CUVRIOR?
2. What indicators best predict when a branded product will lose pricing power to generics?
3. How do Paragraph IV settlements change generic launch probabilities and timelines?
4. What patent categories (composition, formulation, method-of-use) most delay generic substitution?
5. How does supply continuity influence early adoption and long-run persistence for branded therapies?